Hemostasis and Tissue Sealing Agents Market

Market Overview:

The global hemostasis and tissue sealing agents market size reached US$ 6.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.6 Billion by 2028, exhibiting a growth rate (CAGR) of 7.1% during 2023-2028.

Hemostasis is a normal physiological response of the body, which regulates blood fluidity by stopping blood loss from the damaged blood vessel through hemostats. On the other hand, tissue sealing prevents perioperative hemorrhage and controls blood loss from damaged tissues through tissue sealing agents. Hemostats and tissue sealing agents are both used to compress blood vessels and avoid hemorrhage, blood flow, and other fluid discharge. They include thrombin sealant, fibrin glue, bovine serum or albumin, and gelatin matrix. They ensure blood fluidity and blood vessel integrity and help reduce wound healing and operative time, minimize the recovery time and hospital stay and provide better management of anticoagulated patients. They are used to disperse raw surface bleeding, bone bleeding, oozing venous bleeds, and needle-opening bleeding. At present, they are easily available in the market with varying compositions, mechanisms of action, cost, application, and adherence.

Hemostasis and Tissue Sealing Agents Market Trends:

The increasing global geriatric population and chronic medical conditions represent one of the key factors positively influencing the market. The rising participation of individuals in physical activities, along with the increasing occurrence of injuries caused during workouts and sports and physical activities, is catalyzing the demand for hemostasis and tissue sealing agents across the globe. In addition, rising cases of road accidents and gastrointestinal, pulmonary, and cardiovascular surgeries are increasing the demand for hemostats and tissue sealing. Apart from this, shifting consumer preference toward minimally invasive surgeries (MIS) for minimal incision and blood loss and faster recovery time is offering lucrative growth opportunities to manufacturers. Furthermore, leading market players are focusing on the development of multi-usage and ready-to-use products, which is expected to propel market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemostasis and tissue sealing agents market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, material type, application and end user.

Breakup by Product Type:

• Topical Hemostats
• Adhesive and Tissue Sealant
   

Breakup by Material Type:

• Collagen-based
• Oxidized Regenerated Cellulose (ORC) based
• Gelatin-based
• Polysaccharide-based
• Others
   

Breakup by Application:

• General Surgery
• Minimally Invasive Surgery
• Others
   

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
• Home Care Settings
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Advance Medical Solution Group Plc., Artivion Inc., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson & Company, Integra LifeSciences Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Smith & Nephew plc and Terumo Corporation.

Report Coverage: